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Abstract
Patients with advanced stage invasive cervical cancer (CC) exhibit highly
complex genomic alterations and respond poorly to conventional treatment
protocols. In our efforts to understand the molecular genetic basis of CC, we
examined the role of Fanconi Anemia (FA)-BRCA pathway. Here, we show
that FANCF gene is disrupted by either promoter hypermethylation and/or
deregulated gene expression in a majority of CC. Inhibition of DNA methy-
lation and histone deacetylases induces FANCF gene re-expression in CC cell
lines. FANCF-deregulated CC cell lines also exhibit a chromosomal hyper-
sensitivity phenotype after exposure to an alkylating agent, a characteristic of
FA patients. We also show the involvement of BRCA1 gene by promoter
hypermethylation or down-regulated expression in a small subset of CC
patients. Thus, we have found inactivation of genes in the FA-BRCA pathway
by epigenetic alterations in a high proportion of CC patients, suggesting a
major role for this pathway in the development of cervical cancer. Thus, these
results have important implications in understanding the molecular basis of
CC tumorigenesis and clinical management in designing targeted experimen-
tal therapeutic protocols.
Introduction
Approximately 500,000 new cases of cervical cancer (CC) are diag-
nosed worldwide each year, and the majority of affected women with
advanced cancer die (1). Human papillomavirus is considered as a com-
mon risk factor for CC. Most women with early-stage tumors can be
cured by surgery and radiotherapy. However, treatment of late-stage and
recurrent CC remains largely ineffective. The poor prognosis of advanced
CC is due to lack of understanding of its biology at the molecular level
and of effective treatment regimens. CC cells harbor complex genomic
alterations and are highly unstable (2). A better understanding of molec-
ular alterations could therefore facilitate the design of new and targeted
therapies for individualized treatment.
Fanconi anemia (FA) is an autosomal recessive chromosomal insta-
bility syndrome characterized by hypersensitivity to DNA cross-linking
agents and predisposition to cancer, especially leukemia (3). FA patients
are also prone to various solid malignancies, including squamous cell
carcinoma. The lifetime risk for developing CC in FA patients is also
significantly higher than in control populations (3, 4). FA is a genetically
heterogeneous disease with genes for seven FA complementation
(FANC) groups identified (5). FANC genes are essential in DNA repair
pathways in a normal cellular response to cisplatin and other DNA
cross-linking agents. FANC proteins interact with BRCA genes in a
pathway that involves a number of other genes (6). Recently, it has been
shown that promoter hypermethylation of FANCF gene disrupts the
FA-BRCA pathway, resulting in cisplatin resistance (7). FANCF pro-
moter hypermethylation has also shown to occur in squamous cell car-
cinomas of lung and oral cavity (8).
Because FA patients exhibit an increased risk for the development of
CC, we investigated whether the FA-BRCA pathway is altered in this tumor.
Materials and Methods
Patients, Tumor Tissues, and Cell Lines. A total of 100 CC DNA samples
derived from 91 at-diagnosis tumor biopsies from invasive CCs and nine cell lines
was used in these studies. The tumor biopsies were ascertained from patients
evaluated at the Instituto Nacional de Cancerologia (Santa Fe de Bogota, Colom-
bia) and from the Department of Obstetrics and Gynecology of Friedrich Schiller
University (Jena, Germany) after appropriate informed consent and approval of
protocols by Institutional Review Boards. The primary tumors were clinically
classified as International Federation of Gynecologists and Obstetricians stage IB
(18 tumors), IIB (23 tumors), IIIB (47 tumors), and IV (3 tumors). Histologically,
86 tumors were classified as squamous cell carcinoma and 5 as adenocarcinoma.
Clinical information was collected as described previously (9). Follow-up ranged
from 1 to 72 months. Cytologically diagnosed cervical swabs from 18 normal, 11
atypical squamous cells of undetermined significance, 19 low- and 7 high-grade
squamous intraepithelial lesions were collected in PBS from patients attending the
Gynecologic Oncology Clinic at Columbia University Medical Center (New York,
NY), after appropriate informed consent. The CC cell lines HeLa, SiHa, SW756,
C-4I, Ca Ski, C-33A, HT-3, MS751, and ME-180 were obtained from the Amer-
ican Type Culture Collection (Manassas, VA) and grown in tissue culture accord-
ing to the supplier’s recommendations. DNA and/or RNA were isolated from
frozen tumor tissues or cell pellets by standard methods. RNA was obtained from
20-m sections with H&E staining of adjacent sections to evaluate for tumor
content. Only sections that contained 70% tumor cells were used for RNA
preparation.
Methylation-Specific PCR. Genomic DNA was treated with sodium bisul-
fite as described previously (9). Placental DNA treated in vitro with SssI
methyltransferase (New England Biolabs, Beverly, MA) and normal lympho-
cyte DNA treated similarly with sodium bisulfite were used as controls for
methylated and unmethylated templates, respectively. The primers for ampli-
fication of methylated and unmethylated promoters of BRCA1, BRCA2, and
FANCF (two sets covering regions 86 to 97 and 279 to 431 bp) were
designed as described previously (9). PCR products were run on 2% agarose
gels and visualized after ethidium bromide staining.
Mutation Analysis and Human Papillomavirus Detection. Six sets of prim-
ers covering the coding region of FANCF gene were designed to amplify genomic
sequences up to 250 bp. Single-strand conformation polymorphism analysis was
performed on PCR products generated in the presence of  [32P]dCTP and running
6% nondenaturing polyacrylamide gels containing 10% glycerol. Purified PCR
products from representative tumors were sequenced to identify mutations. Human
papillomavirus types were identified as described earlier (9).
Drug Treatment and Chromosome Preparations. Cells in culture were
treated with mitomycin C at a concentration of 20, 40, or 80 ng for 48 h and
exposed to Colcemid for the last 2 h. Metaphases were prepared by standard
protocols. A total of 100–150 metaphases was analyzed from replicate exper-
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iments to identify chromatid- and chromosome-type aberrations. Cell lines
were treated with 5-aza-2deoxycytidine (Aza-C) and trichostatin (TSA) as
described previously (9).
Reverse Transcription-PCR Analysis. Total RNA isolated from treated
and untreated cell lines, tumor tissues, and three normal cervix uteri obtained
from different commercial sources was reverse transcribed as described pre-
viously (9). A multiplex semiquantitative analysis of gene expression of
BRCA1, BRCA2, FANCFA, FANCC, FANCE, FANCF, and FANCG was
performed in replicate experiments as described previously (9). A given gene
was considered down-regulated in a tumor when the level of mRNA was less
than mean-2SD calculated from the expression in normal cervix. All primers
used in the present study are available from the authors upon request.
Oligonucleotide Microarray Gene Expression Analysis. Biotinylated
cRNA preparation and hybridization to Affymetrix U133A oligonucleotide mi-
croarray (Affymetrix, Santa Clara, CA), which contains 33,000 genes, was per-
formed by the standard protocols supplied by the manufacturer. Arrays were
subsequently developed and scanned to obtain quantitative gene expression levels.
Expression values for the genes were determined using the Affymetrix GENE-
CHIP software and the Global Scaling option, which allows a number of exper-
iments to be normalized to one target intensity to account for the differences in
global chip intensity. To perform the supervised gene expression analysis, we used
the Genes@Work software platform, which is a gene expression analysis tool
based on the pattern discovery algorithm Structural Pattern Localization Analysis
by Sequential Histograms (10, 11). The support value for the analysis was chosen
as n  no – 2 (no, number of samples in each of the two groups).
Statistical Analysis. Association between promoter hypermethylation and
various clinical and genetic characteristics was performed using a 2 test.
Results and Discussion
FANCF and BRCA1 Genes Are Hypermethylated in CC. We
previously reported that the 11p15 region to which the FANCF gene
maps exhibit frequent loss of heterozygosity (LOH) in CC (12, 13).
Because the FA-BRCA pathway has been shown to be disrupted by
promoter hypermethylation of FANCF gene in ovarian, lung, and oral
cancers (7, 8), we reasoned that FANCF gene may be the target tumor
suppressor at 11p15 LOH in CC. To test this hypothesis, we examined
the status of FANCF promoter hypermethylation in DNA samples from
18 normal cervical epithelia and 100 CC. FANCF promoter hypermethy-
lation was not detected in normal cervical epithelium. However, hyper-
methylation was found in 30% of primary tumors (27 of 91 specimens)
as well as in three of nine cell lines (Fig. 1; Table 1). We previously
reported the status of 11p LOH in 42 of the primary tumors included in
the present study (13). Fourteen of the 42 had an 11p LOH. Promoter
hypermethylation of FANCF was observed in 5 of the 14 (35.7%) tumors
that exhibited 11p LOH compared with 6 of 28 (21.4%) tumors without
evidence of 11p LOH. These differences were statistically not significant,
suggesting that the changes affecting 11p by LOH and promoter hyper-
methylation in CC may be independent events.
Correlation of FANCF hypermethylation with clinicopathological
features showed no relationship with stage, size of the tumor, clinical
outcome, and human papillomavirus type. However, patients 45
years showed a significantly higher frequency of promoter methyla-
tion compared with the patients 45 years of age (44.4%; 20 of 45
tumors versus 15.2%; 7 of 46 tumors; P  0.001). These data,
therefore, suggest that FANCF promoter hypermethylation plays a
role in initiation or progression of CC in younger patients. It has also
been previously reported that inherited or somatic mutations in
FANCC and FANCG genes predispose to pancreatic cancer at younger
age (14). Taken together, these results suggest that alterations of genes
in the FA-BRCA pathway may result in increased risk for the devel-
opment of cancer in younger age group patients.
Promoter hypermethylation is also known to inactivate other genes in
the FA-BRCA pathway, including BRCA1 and BRCA2 (15). In the same
cohort of cases studied here, we previously reported BRCA1 promoter
hypermethylation in 6.1% of CC patients (9). Promoter hypermethylation
of FANCF and BRCA1 genes was mutually exclusive in these tumors. In
the present study, we also studied BRCA2 promoter methylation and
found it in none of the tumors. The frequency of FANCF promoter
hypermethylation seen in the present study is the highest in any tumor
reported thus far (7, 8). Thus, in 35% of CC patients, either FANCF or
BRCA1 was inactivated by promoter hypermethylation, suggesting a
major role for the FA-BRCA pathway in this tumor. To identify the role
of FANCF in CC progression, we studied DNA obtained from 37 pap
smears diagnosed at various stages of precancerous lesions by methyla-
tion-specific PCR and found no evidence of hypermethylation of the
promoter, suggesting that the FANCF inactivation is a late event in the
tumor development.
FANCF Expression Is Down-Regulated in Most CC Cell Lines.
The FA proteins (Fanca, Fancc, Fance, Fancf, and Fancg) that are
ubiquitously expressed in dividing normal cells play a major role by
forming nuclear complex mediating monoubiquitination of Fancd2 in
response to DNA damage (6). To test the role of FA-BRCA pathway
genes, BRCA1, BRCA2, and five FANC genes (FANCA, FANCC,
FANCE, FANCF, and FANCG) were studied for the expression by
semiquantitative reverse transcription-PCR analysis in CC cell lines
and/or primary tumors. Examination of steady-state levels of BRCA1 and
BRCA2 genes in nine cell lines and 7 primary tumors, which did not
exhibit promoter methylation of these genes, showed no evidence of
down-regulated expression of BRCA2. However, a relative decrease in
Fig. 1. Methylation-specific PCR analysis of FANCF gene in cervical cancer cell lines
and primary tumors. U, unmethylated; M, methylated. T, tumor.









CaSki No     Low
HT-3 No     NDb
SiHa Yes 2    ND
ME-180 Yes 2    High
SW756 Yes 2    High
MS751 No 2    ND
C-4I No 2    High
HeLa No 2    ND
C-33A No     ND
a Downward arrow, complete lack of or decreased expression compared to expression in normal cervix; , expression similar to normal cervix;  and  indicate increased
levels of expression.
b ND, not done.
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the expression of BRCA1 was found in 3 of 7 (43%) primary tumors but
not in the cell lines (Fig. 2B).
We then examined the levels of mRNA of five FA genes (FANCA,
FANCC, FANCE, FANCF, and FANCG) in nine CC cell lines. The
FANCA, FANCC, FANCE, and FANCG genes showed no evidence of
decreased expression (data not shown). However, the FANCF gene
showed a down-regulated expression in all three cell lines (SiHa, SW756,
and ME-180) that exhibited promoter hypermethylation (Fig. 2A). In
addition, three other cell lines (C-4I, MS751, and HeLa), which did not
show promoter methylation, also showed down-regulated FANCF
mRNA compared with normal cervix (Fig. 2A; Table 1). Overall, six of
nine (66.6%) cell lines exhibited FANCF gene down-regulation. Thus,
the present results suggest that FANCF is inactivated by mechanisms
other than complete methylation of its promoter such as partial methyl-
ation or mutation. To evaluate the latter possibility, we examined muta-
tions in the coding region in a panel of 16 methylated and 16 unmethy-
lated CC. No nonsense or frameship mutations could be found. However,
this analysis identified five different sequence variants present both in
tumor as well as in the corresponding peripheral blood DNA, four in the
coding region and one at the 5-noncoding region, that were not reported
in the single nucleotide polymorphism (SNP) database.8 These were
TCG3TTG at the 10 position, CGC3CGT at codon Arg32 without
change in amino acid, GCC3GTC that changes Ala1863Val,
AAG3AGG that changes Lys2033Arg, and CCT3CTT that changes
Pro3203Leu. The Pro320Leu has previously been reported as a normal
variant (16). Whether these germ-line variants truly represent polymor-
phisms or inherited mutations that predispose the patients to cancer
remain to be tested.
Because FANCF is a component of FA complex and plays a crucial
role in DNA damage repair by mediating downstream FANCD2
monoubiquitination, we wanted to examine if gene expression differ-
ences exist between tumors carrying hypermethylated and unmethy-
lated FANCF promoter (6). Supervised analysis of expression profile
of 7 FANCF methylated tumors and 8 unmethylated tumors identified
a small number of 12 genes differentially expressed between the two
groups (Fig. 3). Microarray analysis confirmed FANCF expression is
associated with promoter hypermethylation (Fig. 3). Nucleoplasmin
(NPM1) is the only gene that showed higher levels of expression in
promoter hypermethylated tumors compared with unmethylated tu-
mors. Eleven genes, most of which are members of immune response
family, showed down-regulated expression in FANCF-hypermethyl-
ated tumors (Fig. 3). Role of these genes in relation to DNA repair
pathway is unclear. Therefore, these results suggest that FANCF
inactivation by promoter hypermethylation is only upstream regulator
in DNA damage response, and no consistent quantitative changes in
expression of downstream genes occur in normal cellular conditions.
FANCF Is Reactivated in Response to Cellular Exposure to
Demethylating Agents. To test whether other epigenetic mecha-
nisms such as partial methylation and histone deacetylation play a
role, we examined FANCF expression after treatment with Aza-C,
TSA, or both. Aza-C or TSA induced reactivation of FANCF in all
three cell lines (SiHa, SW756, and ME-180) that exhibited complete
promoter hypermethylation and down-regulated expression. Two ad-
ditional cell lines (C-33A and MS751) without evidence of promoter
hypermethylation also induced FANCF expression in response to
exposure to Aza-C or TSA (Fig. 2C; Table 1). Two other cell lines
(C4-I and HeLa) with unmethylated promoters also induced expres-
sion of FANCF after exposure to TSA but not with Aza-C. Thus,
seven of nine (78%) CC cell lines exhibited deregulated expression by
epigenetic mechanisms of inactivation.
DNA hypermethylation-mediated gene silencing is closely associated
with histone modifications such as methyl-H3-K9. In this regard, DNA-
demethylating agents Aza-C and histone deacetylase inhibitor TSA re-
activates expression of epigenetically silenced genes (17). Although
DNA hypermethylation is essential to maintain repressive state of histone
code, histone modifications precede DNA hypermethylation in silencing
specific genes (18, 19). In the present study, reactivation of FANCF after
exposure to TSA in the absence of promoter methylation suggests that
8 http://www.ncbi.nlm.nih.gov/SNP/.
Fig. 3. Supervised analysis of gene expression in FANCF promoter hypermethylated
and unmethylated cervical cancer. In the matrix, each row represents a gene and each
column represents a sample. The color change in each row represents the gene expression
relative to the mean across the samples. The scale bar at the bottom represents the
difference in the Zge score (expression difference/SD) relative to the mean.
Fig. 2. Semiquantitative analysis of FANCF and BRCA1 expression by reverse tran-
scription-PCR in cervical cancer cell lines and primary tumors. ACTB, -actin; T, primary
tumor; A, FANCF expression in CC. Because FANCF coding region spans in a single
exon, we treated the total RNA with two rounds of DNase to avoid amplifying contam-
inating DNA. Note the down-regulated expression of FANCF in the cell lines C-4I, SiHa,
SW756, MS751, ME-180, and HeLa. B, BRCA1 expression in CC. Decreased levels of
BRCA1 expression was found in T-126, T-214, and T-1798. C, effect of demethylation
and acetylation on FANCF gene expression. Two rounds of DNase treated total RNA was
used in reverse transcription reactions to avoid amplifying contaminating DNA.
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key histone modifications, either by direct or indirect involvement of
promoter methylation, also play a role in down-regulating FANCF gene
expression in CC.
CC Cell Lines Exhibit Chromosomal Hypersensitivity to
Mitomycin C. FA cells exhibit increased chromosome breakage and
multiradial formation after exposure to DNA-damaging agents (20). To
examine the chromosomal sensitivity in relation to FANCF inactivation,
we exposed four cell lines (one without evidence of defects in FANCF
and three with FANCF deregulated expression) to various concentrations
of mitomycin C. The cell lines ME-180 and SW756 with methylated
promoters and the C-4I cell line without a methylated promoter but with
down-regulated and reactivated FANCF expression upon treatment to
TSA showed a several-fold increase in chromosomal breakage, including
multiradials compared with CaSki, a cell line that did not exhibit any
FANCF defect (Fig. 4). Frequency of aberrant metaphases was increased
2–3.5-fold in FANCF-defective cell lines (C-4I, ME-180, and SW756)
compared with the CaSki cell line (Fig. 4C). However, the metaphases
exhibiting multiradial chromosomes were 14–25-fold higher in cell lines
with FANCF epigenetic alteration (Fig. 4D). We also found that the cell
lines C-4I and SW756 exhibit a high frequency of polyploid metaphases
with extensive chromosomal breakage (Fig. 4B). Thus, this pronounced
mitomycin C-induced chromosomal hypersensitivity exhibited by CC
cell lines with FANCF epigenetic alterations is similar to the phenotype
seen in FA patients.
Our results suggest that epigenetic inactivation of FA-BRCA pathway
is common in CC. Tumor cells carrying FANCF or BRCA1 promoter
hypermethylation are hypersensitive to DNA-damaging drugs and may
result in pronounced tumor death because of their underlying defect in
FA-BRCA pathway. It has been shown earlier that progression of ovarian
cancer is related to FANCF promoter hypermethylation and demethyla-
tion of the promoter results in cisplatin resistance (7). Additional studies
are required to determine the role of FANCF promoter hypermethylation
in causing cisplatin resistance in CC. However, identification of this
important molecular pathway may have implications in designing appro-
priate chemotherapy regimen to be used in combination with radiother-
apy and a genotype-based therapy may produce a long-term improvement
in the treatment of advanced stage CC.
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Fig. 4. FANCF inactivated cervical cancer cell lines are
hypersensitive to mitomycin C (MMC) treatment. A,
MMC-induced chromosome breakage in SW756 cell line.
A representative micrograph showing chromosome radials
(arrows). B, a near tetraploid metaphase from C-4I cell
line showing MMC-induced multiple breakages. C and D,
MMC-induced chromosomal aberrations in FANCF-inac-
tivated cell lines. Percentage of aberrant metaphases with
all types of aberrations (C) and multiradials/metaphase
(D) are shown. The cell line CaSki had no evidence of
FANCF defect. C-4I cell line showed no evidence of
FANCF promoter methylation but exhibited down-regu-
lated expression and activation by treatment with TSA.
ME-180 and SW756 cell lines had FANCF promoter
hypermethylation and down-regulated expression.
2997
FANCF PROMOTER HYPERMETHYLATION IN CERVICAL CARCINOMA
